Microbiotica develops defined live biotherapeutic products that target specific gut bacteria to improve outcomes in inflammatory bowel disease and cancer immunotherapy. Using a clinic‑led discovery platform, the company identifies microbes linked to patient responses and creates precision microbiome medicines with known mechanisms of action, intended for use alongside standard therapies.
Funding
$90.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
4OTFounders
Product
Problem
Current treatments for inflammatory bowel disease and cancer immunotherapy often have limited efficacy and significant side effects, while the role of the gut microbiome in modulating patient response remains underexplored.
Solution
Microbiotica develops defined live biotherapeutic products (LBPs) that target specific bacterial strains linked to therapeutic outcomes in ulcerative colitis and advanced melanoma. By leveraging a clinic-led discovery platform, the company identifies microbes that influence immune pathways and formulates precision microbiome medicines with known mechanisms of action. These LBPs are administered alongside standard care to enhance efficacy, reduce adverse events, and personalize treatment for defined patient subpopulations. Clinical-stage programs, such as MB310 for ulcerative colitis and MB097 as a co‑therapy for melanoma, demonstrate the potential of microbiome modulation to improve disease management.
Target Audience
Primary customers are pharmaceutical companies and clinical investigators developing immuno‑oncology or inflammatory bowel disease therapies, as well as healthcare providers seeking microbiome‑based adjunct treatments for these indications.
Features
- Defined, single‑strain or consortia live biotherapeutics with reproducible manufacturing and dosing
- Clinic‑driven microbial discovery pipeline that correlates specific bacteria with patient outcomes
- Mechanism‑based targeting of immune pathways to augment immuno‑oncology and inflammatory bowel disease therapies
- Integration with standard-of‑care regimens, enabling combination treatment strategies
- Clinical‑stage development with Phase 1b data supporting safety and preliminary efficacy